English, Article edition: Economic Evaluation of Systemic Treatments for Cytomegalovirus Retinitis in Patients with AIDS Todd A. Lee; Sean D. Sullivan; David L. Veenstra; ...

User activity

Share to:
 
Bookmark: http://trove.nla.gov.au/version/93670
Physical Description
  • article
Language
  • English

Edition details

Title
  • Economic Evaluation of Systemic Treatments for Cytomegalovirus Retinitis in Patients with AIDS
Author
  • Todd A. Lee
  • Sean D. Sullivan
  • David L. Veenstra
  • Scott D. Ramsey
  • Patrick J.K. Steger
  • Raffaele Malinverni
  • Andreas M. Pleil
  • Todd Williamson
Physical Description
  • article
Notes
  • Objective: To determine the cost of using systemic therapy to treat newly diagnosed cytomegalovirus (CMV) retinitis in persons with AIDS. Design: Incidence-based simulation model of CMV treatment from a government payer perspective. Setting: Swiss healthcare system. Patients and participants: Patients with AIDS and newly diagnosed CMV retinitis. Interventions: Patients were assigned to 1 of 4 treatment regimens for induction and maintenance therapy: 1. intravenous (IV) cidofovir induction and maintenance (cidofovir IV/​IV); 2. IV foscarnet induction and maintenance (foscarnet IV/​IV); 3. IV ganciclovir induction and maintenance (ganciclovir IV/​IV); and 4. IV ganciclovir induction and oral (PO) ganciclovir maintenance (ganciclovir IV/​PO). Following a second relapse, patients were assigned to one of the other regimens. Main outcome measures: Time to first and subsequent progression, duration of maintenance treatment and direct medical expenditures [1998 Swiss francs (SwF)]. Results: The median time to first progression was longest for cidofovir IV/​IV, followed by foscarnet IV/​IV, ganciclovir IV/​IV and ganciclovir IV/​PO. Mean survival was 13 months and mean costs for this period in the base case were lowest in those initially treated with cidofovir (SwF146 742), followed by initial treatment with foscarnet IV/​IV (SwF194 809), ganciclovir IV/​PO (SwF195 190) and ganciclovir IV/​IV (SwF243 964). Costs were most sensitive to changes in efficacy estimates. Conclusions: Of the regimens studied, initiation of treatment with systemic cidofovir appears least costly over a 13-month period.
  • Antivirals, Cidofovir, Cost analysis, Cytomegalovirus infections, Foscarnet, Ganciclovir, Pharmacoeconomics, Retinitis
  • RePEc:wkh:phecon:v:19:y:2001:i:5:p:535-550
Language
  • English
Contributed by
OAIster

Get this edition

  • Set up My libraries

    How do I set up "My libraries"?

    In order to set up a list of libraries that you have access to, you must first login or sign up. Then set up a personal list of libraries from your profile page by clicking on your user name at the top right of any screen.

  • All (1)
  • Unknown (1)
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.

User activity


e.g. test cricket, Perth (WA), "Parkes, Henry"

Separate different tags with a comma. To include a comma in your tag, surround the tag with double quotes.

Be the first to add a tag for this edition

Be the first to add this to a list

Comments and reviews

What are comments? Add a comment

No user comments or reviews for this version

Add a comment